Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Neurobiol Aging. 2017 Jan 3;52:81–89. doi: 10.1016/j.neurobiolaging.2016.12.022

Figure 1.

Figure 1

In the young-old (YO) group, APOE ε4+ carriers performed worse at age 63 and had steeper 9-year decline in EF than their non-risk (ε4-) counterparts. In the old-old (OO) group APOE ε4+ carriers showed steeper 9-year decline on EF than their non-risk counterparts.